DexCom (DXCM) has released preliminary, unaudited financial results for the fourth quarter of 2025, reporting revenue of $725 million, reflecting a 17% year-over-year increase. The company also noted continued growth in active users, now exceeding 1.2 million globally.
- Q4 2025 revenue: $725 million, a 17% year-over-year increase
- Active users: 1.2 million at quarter-end, up from 1.08 million in Q4 2024
- International revenue accounted for 38% of total revenue in Q4 2025
- Preliminary results are unaudited and not subject to external review
- User growth and international expansion trends are consistent with long-term strategy
- Formal earnings release expected to follow in early February 2026
DexCom (DXCM) has announced preliminary, unaudited results for the fourth quarter of 2025, highlighting robust revenue growth driven by sustained demand for its continuous glucose monitoring (CGM) systems. The company reported total revenue of $725 million, marking a 17% increase compared to the same period in 2024. This performance underscores the expanding adoption of DexCom’s technology across both the U.S. and international markets. The company’s active user base reached 1.2 million at the end of Q4 2025, up from 1.08 million in the prior-year quarter. This growth reflects continued integration of DexCom’s products into diabetes management protocols and increasing acceptance among healthcare providers and patients. The company also noted strong performance in its international segment, which accounted for 38% of total revenue in the quarter—up from 34% in Q4 2024—indicating progress in market expansion efforts. While the results are preliminary and not subject to external audit, they provide early visibility into DexCom’s financial trajectory ahead of its formal earnings release. The company has not provided guidance for Q1 2026, but the positive momentum suggests continued investor interest in its long-term prospects. The unaudited figures are consistent with recent industry trends in digital health and remote patient monitoring, particularly in chronic disease management. The results are expected to influence trading activity for DXCM stock in the coming weeks, particularly as the broader healthcare sector braces for earnings season. Investors and analysts will be closely monitoring the company’s path toward profitability improvements and expansion into new use cases, such as integrated insulin delivery systems and predictive analytics.